There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Oncolytics Biotech (ONCY – Research Report) and Lineage Therap (LCTX – Research Report) with bullish sentiments.
Oncolytics Biotech (ONCY)
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Oncolytics Biotech, with a price target of $5.00. The company’s shares closed last Friday at $1.17, close to its 52-week low of $0.88.
According to TipRanks.com, McCarthy is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Oncolytics Biotech has an analyst consensus of Strong Buy, with a price target consensus of $4.62.
See Insiders’ Hot Stocks on TipRanks >>
Lineage Therap (LCTX)
In a report released yesterday, Michael Okunewitch from Maxim Group maintained a Buy rating on Lineage Therap, with a price target of $5.00. The company’s shares closed last Friday at $1.17.
According to TipRanks.com, Okunewitch is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Lineage Therap is a Strong Buy with an average price target of $5.25, a 356.5% upside from current levels. In a report issued on May 6, Robert W. Baird also maintained a Buy rating on the stock with a $5.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ONCY:
